GlassScriptPhysician profile
Lasondra Bean
NPI 1710126941
$5,898.78
in general payments reported to CMS, 2019-2025
60 companies · $2,503 in 2025
The $2,503 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.38 · 2023: $712 · 2024: $2,671 · 2025: $2,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,484 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,484.48 |
| Education | $401.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $732.58 | 2023-2025 | |
| Daiichi Sankyo INC. | $651.69 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Novartis Pharmaceuticals Corporation | $478.81 | 2023-2025 | |
| Janssen Biotech, INC. | $408.15 | 2024-2025 | Talvey, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $355.90 | 2024-2025 | Lynparza, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $337.96 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Abbvie INC. | $205.57 | 2023-2025 | |
| Amgen INC. | $200.55 | 2025 | Nplate |
| Gilead Sciences, INC. | $172.41 | 2023-2025 | Trodelvy |
| Celgene Corporation | $160.05 | 2024-2025 | Reblozyl, Opdivo |
| Genzyme Corporation | $147.10 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $117.96 | 2025 | Onivyde |
| Sobi, INC | $105.17 | 2023-2024 | |
| Lilly USA, LLC | $91.51 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $87.83 | 2024-2025 | Libtayo |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $87.40 | 2023-2025 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $82.87 | 2024-2025 | Monoferric, Cosela |
| Astellas Pharma US INC | $80.35 | 2023-2024 | Xospata, Vyloy, Xtandi |
| Pharmaessentia USA Corporation | $76.71 | 2024-2025 | Besremi |
| E.R. Squibb & Sons, L.L.C. | $72.28 | 2024-2025 | Opdivo, Krazati, Augtyro |
| Incyte Corporation | $69.04 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Stemline Therapeutics INC. | $60.07 | 2024-2025 | Orserdu, Elzonris |
| Eisai INC. | $51.52 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $50.28 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Coherus Oncology, INC. | $48.09 | 2024-2025 | Loqtorzi |
| Genmab U.S., INC. | $46.58 | 2024 | Tivdak |
| Emd Serono, INC. | $45.29 | 2024 | |
| Beigene USA, INC. | $45.24 | 2024-2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $43.44 | 2023-2024 | Xpovio |
| Glaxosmithkline, LLC. | $42.66 | 2023-2025 | Ojjaara, Blenrep |
| Seagen INC. | $41.72 | 2023 | Tukysa, Adcetris |
| Alexion Pharmaceuticals, INC. | $41.27 | 2024-2025 | Ultomiris |
| Puma Biotechnology, INC. | $39.93 | 2023-2025 | Nerlynx |
| Takeda Pharmaceuticals U.S.A., INC. | $39.93 | 2024-2025 | Iclusig, Fruzaqla |
| Octapharma USA, INC. | $38.87 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Servier Pharmaceuticals LLC | $36.40 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $36.29 | 2024-2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $33.64 | 2024-2025 | |
| Geron Corporation | $31.71 | 2025 | Rytelo |
| Genentech USA, INC. | $31.62 | 2023-2024 | Lunsumio, Polivy, Columvi |
| Bayer Healthcare Pharmaceuticals INC. | $30.49 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $25.32 | 2024 | Empaveli |
| Alnylam Pharmaceuticals INC. | $23.27 | 2024 | Onpattro |
| Sumitomo Pharma America, INC. | $23.09 | 2024 | Orgovyx |
| Morphosys, US INC. | $22.11 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $21.50 | 2023 | |
| Fennec Pharmaceuticals, INC. | $20.93 | 2025 | Fyarro |
| Accord Healthcare, INC. | $20.79 | 2025 | |
| Corium, LLC | $20.46 | 2025 | Azstarys |
| Cumberland Pharmaceuticals, INC. | $20.27 | 2024 | Sancuso |
| Adc Therapeutics America, INC. | $16.02 | 2025 | |
| Spectrum Pharmaceuticals INC. | $15.92 | 2025 | Rolvedon |
| Tersera Therapeutics LLC | $15.76 | 2024 | Zoladex |
| Springworks Therapeutics, INC. | $15.56 | 2024 | Ogsiveo |
| Immunocore Limited | $14.79 | 2025 | Kimmtrak |
| Iovance Biotherapeutics, INC. | $14.63 | 2025 | Amtagvi |
| Mirati Therapeutics, INC. | $13.77 | 2024 | Krazati |
| Recordati_rare_diseases_inc. | $13.56 | 2023 | Sylvant |
| Pharmacyclics LLC, An Abbvie Company | $12.38 | 2021 | |
| Array Biopharma INC | $11.72 | 2025 | Braftovi, Tukysa, Mektovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lasondra Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.